Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 2746 AL 2760

ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease

Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, Ropele S, Fialova L, Kramberger M, Paulenka-Ivanovova N, Smisek M, Hanes J, Stevens E, Kovac A, Sutovsky S, Parrak V, Koson P, Prcina M, Galba J, Cente M, Hromadka T, Filipcik P, Piestansky J, Samcova M, Prenn-Gologranc C, Sivak R, Froelich L, Fresser M, Rakusa M, Harrison J, Hort J, Otto M, Tosun D, Ondrus M, Winblad B, Novak M, Zilka N.

Nat Aging. 2021 Jun;1(6):521-534. doi: 10.1038/s43587-021-00070-2. Epub 2021 Jun 14.

Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment

Nakai T, Yamada K, Mizoguchi H.

Int J Mol Sci. 2021 May 24;22(11):5549. doi: 10.3390/ijms22115549.

Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease

Kellar D, Lockhart SN, Aisen P, Raman R, Rissman RA, Brewer J, Craft S.

J Prev Alzheimers Dis. 2021;8(3):240-248. doi: 10.14283/jpad.2021.14.

Lithium: A therapeutic option in Alzheimer's disease and its prodromal stages?

Haussmann R, Noppes F, Brandt MD, Bauer M, Donix M.

Neurosci Lett. 2021 Aug 24;760:136044. doi: 10.1016/j.neulet.2021.136044. Epub 2021 Jun 10.

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease

Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Cruchaga C, Goate AA, Perrin RJ, Xiong C, Li Y, Morris JC, Snider BJ, Mummery C, Surti GM, Hannequin D, Wallon D, Berman SB, Lah JJ, Jimenez-Velazquez IZ, Roberson ED, van Dyck CH, Honig LS, Sánchez-Valle R, Brooks WS, Gauthier S, Galasko DR, Masters CL, Brosch JR, Hsiung GR, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Jack CR Jr, Koeppe R, Snyder PJ, Aisen PS, Thomas RG, Berry SM, Wendelberger BA, Andersen SW, Holdridge KC, Mintun MA, Yaari R, Sims JR, Baudler M, Delmar P, Doody RS, Fontoura P, Giacobino C, Kerchner GA, Bateman RJ; Dominantly Inherited Alzheimer Network–Trials Unit.

Nat Med. 2021 Jul;27(7):1187-1196. doi: 10.1038/s41591-021-01369-8. Epub 2021 Jun 21.

Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease

Athar T, Al Balushi K, Khan SA.

Mol Biol Rep. 2021 Jul;48(7):5629-5645. doi: 10.1007/s11033-021-06512-9. Epub 2021 Jun 28.

Therapeutic potential of astaxanthin and superoxide dismutase in Alzheimer's disease

Balendra V, Singh SK.

Open Biol. 2021 Jun;11(6):210013. doi: 10.1098/rsob.210013. Epub 2021 Jun 30.

Bridging Cyanobacteria to Neurodegenerative Diseases: A New Potential Source of Bioactive Compounds against Alzheimer's Disease

Castaneda A, Ferraz R, Vieira M, Cardoso I, Vasconcelos V, Martins R.

Mar Drugs. 2021 Jun 16;19(6):343. doi: 10.3390/md19060343.

The next step of neurogenesis in the context of Alzheimer's disease

Moradi HR, Hajali V, Khaksar Z, Vafaee F, Forouzanfar F, Negah SS.

Mol Biol Rep. 2021 Jul;48(7):5647-5660. doi: 10.1007/s11033-021-06520-9. Epub 2021 Jul 7.

Role of TREM2 in Alzheimer's Disease: A Long Road Ahead

Kulkarni B, Kumar D, Cruz-Martins N, Sellamuthu S.

Mol Neurobiol. 2021 Oct;58(10):5239-5252. doi: 10.1007/s12035-021-02477-9. Epub 2021 Jul 18.

Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials

Mortby ME, Adler L, Agüera-Ortiz L, Bateman DR, Brodaty H, Cantillon M, Geda YE, Ismail Z, Lanctôt KL, Marshall GA, Padala PR, Politis A, Rosenberg PB, Siarkos K, Sultzer DL, Theleritis C; ISTAART NPS PIA.

Am J Geriatr Psychiatry. 2022 Feb;30(2):119-147. doi: 10.1016/j.jagp.2021.06.016. Epub 2021 Jul 1.

Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer's disease

Boada M, Martínez-Lage P, Serrano-Castro P, Costa M, Páez A.

Expert Rev Neurother. 2021 Aug;21(8):843-849. doi: 10.1080/14737175.2021.1960823. Epub 2021 Aug 4.

High-density lipoprotein in Alzheimer's disease: From potential biomarkers to therapeutics

Jin Y, Chifodya K, Han G, Jiang W, Chen Y, Shi Y, Xu Q, Xi Y, Wang J, Zhou J, Zhang H, Ding Y.

J Control Release. 2021 Oct 10;338:56-70. doi: 10.1016/j.jconrel.2021.08.018. Epub 2021 Aug 13.

Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease: A Randomized Controlled Trial-The OmegAD Study

Tofiq A, Zetterberg H, Blennow K, Basun H, Cederholm T, Eriksdotter M, Faxén-Irving G, Hjorth E, Jernerén F, Schultzberg M, Wahlund LO, Palmblad J, Freund-Levi Y.

J Alzheimers Dis. 2021;83(3):1291-1301. doi: 10.3233/JAD-210007.

Targeting Endothelin in Alzheimer's Disease: A Promising Therapeutic Approach

Sharma S, Behl T, Kumar A, Sehgal A, Singh S, Sharma N, Bhatia S, Al-Harrasi A, Bungau S.

Biomed Res Int. 2021 Sep 6;2021:7396580. doi: 10.1155/2021/7396580. eCollection 2021.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias